Related Experiment Video
Updated: Sep 11, 2025

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
Gastrointestinal CancerEmerging treatment modalities for gastric cancer with peritoneal metastases: a systematic
Marion Wilhelmina Tops-Welten1,2, Laskarina Jaklien Konstantina Galanos2,3, Geert-Jan Creemers1
1Department of Oncology, Catharina Cancer Institute, Catharina Hospital, Eindhoven 5623 EJ, the Netherlands.
Introduction:
Gastric cancer remains associated with a high mortality, since patients often present with advanced-stage disease such as peritoneal metastases. Treatment options in this setting are limited and mainly consist of palliative systemic therapy.
Objectives:
This systematic review aims to summarize emerging therapeutic strategies for patients with peritoneally metastasized gastric cancer in relation to response, toxicity, and survival.
Methods:
A search was performed in PubMed, EMBASE, and Cochrane database until December 8, 2023. Studies were eligible if they prospectively investigated any form of cancer treatment in adult patients with peritoneally metastasized gastric cancer.
Results:
In total, 25 articles were retrieved from 9 different countries, investigating systemic therapy, intraperitoneal therapy (IP), hyperthermic intraperitoneal chemotherapy (HIPEC) with or without cytoreductive surgery (CRS), and pressurized intraperitoneal aerosol chemotherapy (PIPAC). CRS-HIPEC followed by early postoperative intraperitoneal chemotherapy (EPIC) showed high complication rates and patient drop-out. Median overall survival (OS) ranged from 6.5 to 7.4 months with systemic chemotherapy, 13.0 to 23.9 months with IP chemotherapy, 6.8 to 13.0 months after PIPAC, 11.0 to 19.0 months with CRS-HIPEC, and 9.9 months in elderly with HIPEC alone. Notably, patients with a Peritoneal Cancer Index ≥20 showed median OS ≥13.0 months with IP chemotherapy or HIPEC without CRS.
Conclusion:
Few prospective trials are conducted in patients with peritoneally metastasized gastric cancer. Although IP chemotherapy and CRS-HIPEC show encouraging results in selected cohorts, especially in Asia, current evidence from randomized studies is limited. Further prospective trials are needed to clarify their role alongside the current systemic therapy, including immunotherapy and targeted therapy.
More Related Videos
09:02Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
Published on: July 31, 2016
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Related Concept Videos
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against...
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
Peptic Ulcer Disease V: Surgical Management and Nursing Care
Surgical Interventions for Peptic Ulcer Disease
Tumor Immunotherapy